GLP-1 medicine prices in South Africa
What Ozempic, Wegovy, Mounjaro and the new generic semaglutides cost, who pays for them and what is changing. A 2026 guide.
Last updated 12 November 2026. We update this guide as prices, approvals and funding rules change.
GLP-1 medicines such as Ozempic, Wegovy and Mounjaro have become some of the most sought-after medicines in South Africa. They are registered for type 2 diabetes and, in some cases, weight management. Demand has grown quickly, but so have questions about what they cost, who pays for them and whether cheaper versions are on the way. This guide brings together the latest prices and developments from Health Matters’ reporting.
GLP-1 prices in South Africa at a glance
| Medicine | Active ingredient | Registered for | Price (incl. VAT) |
|---|---|---|---|
| Ozempic (Novo Nordisk) | Semaglutide | Type 2 diabetes | R1,437.78 (1.5ml pen) or R2,875.56 (3ml pen), each pen four weekly doses1 |
| Extensior (Novo Nordisk) | Semaglutide | Type 2 diabetes | R1,222.10 (1.5ml pen) or R2,444.23 (3ml pen), about 15% below Ozempic1 |
| Semagard (Sun Pharma / Ranbaxy) | Semaglutide | Type 2 diabetes | About 18% below Ozempic2 |
| Aspen generic semaglutide | Semaglutide | Type 2 diabetes | Approved November 2026; price not yet announced3 |
| Wegovy (Novo Nordisk) | Semaglutide | Weight management | From R1,873 (lowest dose) to R3,746 (highest dose)4 |
| Mounjaro (Eli Lilly, sold by Aspen) | Tirzepatide | Type 2 diabetes and weight management | From about R3,600 (starting dose)4 |
1 Single exit prices at Extensior’s launch in July 2026. 2 Launch comparison, August 2026. 3 Aspen announcement, 11 November 2026. 4 Prices reported by Reuters in March 2026, after Novo Nordisk’s second Wegovy price cut. Medicine prices rose by an extraordinary 2.88% from 1 October 2026, so current prices may be slightly higher. Pharmacies may add a dispensing fee. Always confirm the price with your pharmacy.
What patients typically pay each month
What you pay depends on the medicine, the dose and whether a medical scheme contributes. Recent estimates vary widely:
- R2,000 to R3,000 a month is what many patients pay, according to Clicks CEO Bertina Engelbrecht in October 2026. Read more
- R2,500 to R6,000 a month, depending on the dose, according to Moneyweb’s reporting on new GLP-1 payment plans in September 2026. Read more
- R3,000 to R10,000 a month across products and doses, according to Bhekisisa in August 2026. Read more
Doses usually start low and increase over several weeks, so the monthly cost often rises after the first few months of treatment.
Does medical aid cover GLP-1 medicines?
Cover is limited. Obesity is not a prescribed minimum benefit, so medical schemes are not obliged to fund medicines used only for weight loss from their risk benefits. Some schemes fund GLP-1 medicines for type 2 diabetes under strict clinical criteria, and most patients using them for weight management pay themselves.
Use is nevertheless rising fast. Paid GLP-1 claims among Discovery Health Medical Scheme members rose from about 22,400 in 2022 to 61,200 in 2025, and Discovery’s Vitality programme now offers doctor-led weight assessments that can lead to a prescription. Read more Discovery said the lower price of Extensior was a positive step but unlikely, on its own, to change its funding criteria. Read more
Generic semaglutide and where prices are heading
Novo Nordisk’s South African patent on semaglutide expired in 2026, opening the market to competitors:
- Extensior, Novo Nordisk’s own lower-priced semaglutide, launched on 31 July 2026.
- Semagard, Sun Pharma’s generic, launched in August 2026 as the first generic semaglutide in South Africa.
- Aspen received approval for its generic semaglutide in November 2026 and plans to launch in the coming months. Read more
- The South African Health Products Regulatory Authority (SAHPRA) is reviewing more than a dozen further semaglutide applications.
Early discounts have been modest, at around 15% to 18% below Ozempic. But more competitors should push prices lower. Clicks expects prices to fall significantly over the next two to three years, and a study co-authored by Wits University researcher Francois Venter estimated that semaglutide could be produced for about R100 to R200 a month.
GLP-1 medicines in the public sector
GLP-1 medicines are not yet available to most public sector patients. The National Essential Medicines List Committee is assessing whether to add them to the essential medicines list for diabetes, including whether the state can afford them. Read more A separate review of their use for obesity had not started as of October 2026, even though the World Health Organisation recommended them for long-term obesity management in December 2025. Read more
Safety, illegal products and new warnings
High prices have fuelled a market for unregistered and illegally compounded GLP-1 products. SAHPRA and the South African Pharmacy Council raided a Pretoria compounding pharmacy in May 2026 and have warned that unregistered products may contain incorrect doses or contaminants. Read more Tighter compounding standards are expected in early 2027, and manufacturers have called for prosecutions over the sale of unapproved medicines such as retatrutide. Read more
In November 2026, the US Food and Drug Administration ordered new warnings about a rare eye condition, NAION, across GLP-1 medicines. The absolute risk is small, but patients should report sudden vision changes to a doctor immediately. Read more
Latest GLP-1 news from Health Matters
- Generic Semaglutide From Aspen Wins Approval in South Africa and Brazil
- GLP-1 Eye Risk: FDA Orders New Warnings
- GLP-1 Obesity Treatment Review Yet to Start in SA
- Clicks Growth Strategy Targets GLP-1 Medicines, Oncology
- Illegal Weight-Loss Medicines Face Regulatory Crackdown
- GLP-1 Obesity Support Expanded by Vitality
This guide is for general information and industry awareness. It is not medical advice. Prices change and may differ between pharmacies. Speak to your doctor or pharmacist about whether a GLP-1 medicine is right for you. Get the week’s healthcare news free with Health Matters Weekly.